Lineage Cell Therapeutics (LCTX) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lineage Cell Therapeutics is the larger company by market cap ($260.5 million vs $259.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | VOGX |
|---|---|---|
| Share price | $1.03 | $17.49 |
| Market cap | $260.49M | $259.82M |
| 1-day change | +8.70% | +8.23% |
| YTD return | -38.32% | — |
| 1-year return | -40.46% | — |
| 5-year return | -56.17% | — |
| EPS (TTM) | $-0.19 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $38.41 |
| 52-week low | $0.88 | $12.95 |
| Distance from 52-week high | -50.72% | -54.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +433.98% | +214.47% |
| Average volume | 1.15M | 187.66K |
| Shares outstanding | 252.91M | 14.86M |
| Employees | 72 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 72 employees
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
LCTX vs VOGX FAQ
Which is bigger, Lineage Cell Therapeutics or Vogenx?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $260.49M compared with $259.82M for Vogenx (VOGX).
Are Lineage Cell Therapeutics and Vogenx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Lineage Cell Therapeutics and Biotechnology: Pharmaceutical Preparations for Vogenx.